Larimar Therapeutics (LRMR) to Release Earnings on Thursday

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Larimar Therapeutics to post earnings of ($0.42) per share for the quarter.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04). On average, analysts expect Larimar Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Larimar Therapeutics Stock Down 9.9 %

NASDAQ LRMR traded down $0.27 during trading hours on Tuesday, reaching $2.43. 758,733 shares of the company were exchanged, compared to its average volume of 731,453. The stock has a market capitalization of $155.27 million, a P/E ratio of -2.12 and a beta of 0.93. Larimar Therapeutics has a 1 year low of $1.61 and a 1 year high of $11.20. The business's 50 day simple moving average is $2.36 and its 200-day simple moving average is $4.17.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. HC Wainwright lifted their price target on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a report on Tuesday, March 25th. Robert W. Baird dropped their price target on Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 25th. Guggenheim reissued a "buy" rating and issued a $26.00 price objective on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Truist Financial began coverage on shares of Larimar Therapeutics in a report on Wednesday, January 29th. They set a "buy" rating and a $18.00 price objective on the stock. Finally, Citigroup reissued a "buy" rating on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $19.63.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.